Such fees had previously been recognized when received, but now are being recognized over the term of the contract. Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. There can be no assurance that Tularik will obtain necessary regulatory approvals for its drug candidates or be able to develop a commercially viable pharmaceutical product. These and other risks are more fully discussed in Tularik s SEC reports, including the report on Form 10-K for the year ended December 31, 1999. Derived from audited consolidated financial statements at that date.
Press releases are only accurate as of their respective dates.
Tularik does not undertake to update this information included in any press release.